Active surveillance for prostate cancer with selective delayed definitive therapy

Clinical Prostate Cancer

Volumn 4, Issue 1, 2005, Pages 45-49

  Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Digital rectal examination; Gleason score; PSA doubling time; Watchful waiting

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANXIETY; BEAM THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CONSERVATIVE TREATMENT; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; EARLY DIAGNOSIS; GLEASON SCORE; HEALTH STATUS; HUMAN; INCONTINENCE; LIFE EXPECTANCY; MEDICAL DECISION MAKING; PATIENT MONITORING; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 22544444531     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.011     Document Type: Review

References (21)

1. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379-385.
2. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23:211-222.
3. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995. NIH Pub. No. 99-4543 ed. Bethesda, MD: SEER Program, National Cancer Institute 1999.
4. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter [published erratum in N Engl J Med 2004; 351:1470]. N Engl J Med 2004; 350:2239-2246.
6. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1C) prostate cancer. JAMA 1994; 271:368-374.
7. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1C prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160:2407-2411.
8. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170:1792-1797.
9. Zietman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001; 166:1702-1706.
10. Carter HB, Walsh PC, Landis P, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167:1231-1234.
11. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167:1664-1669.
12. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171:1520-1524.
13. Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172:S48-50.
14. el-Geneidy M, Garzotto M, Panagiotou I, et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int 2004; 93:510-515.
15. Do V, Choo R, De Boer G, et al. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int 2002; 89:703-709.
16. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003; 170:2274-2278.
17. Gerber GS, Gornik HL, Goldfischer ER, et al. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol 1998; 159:1243-1246.
18. Stephenson AJ, Aprikian AG, Souhami L, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59:652-656.
19. Choo R, DeBoer G, Klotz L, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50:615-620.
20. de Vries SH, Raaijmakers R, Kranse R, et al. Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. J Urol 2004; 172:2193-2196.
21. Panagiotou I, Beer TM, Hsieh YC, et al. Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen. Oncology 2004; 67:194-202.